<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; triumph</title>
	<atom:link href="http://www.tapanray.in/tag/triumph/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India’s Push for Affordable Mental Health Meds: Triumphs and Challenges in 2025</title>
		<link>http://www.tapanray.in/indias-push-for-affordable-mental-health-meds-triumphs-and-challenges-in-2025/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-push-for-affordable-mental-health-meds-triumphs-and-challenges-in-2025</link>
		<comments>http://www.tapanray.in/indias-push-for-affordable-mental-health-meds-triumphs-and-challenges-in-2025/#comments</comments>
		<pubDate>Sun, 03 Aug 2025 07:02:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[achievements]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Ghana]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[triumph]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10951</guid>
		<description><![CDATA[In June 2025, a small clinic in rural Ghana celebrated a milestone: it provided affordable antidepressants to 500 patients, thanks to India’s generic sertraline, costing just $2 a month per person. This was unimaginable a decade ago, when branded versions &#8230; <a href="http://www.tapanray.in/indias-push-for-affordable-mental-health-meds-triumphs-and-challenges-in-2025/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-push-for-affordable-mental-health-meds-triumphs-and-challenges-in-2025/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Impact of Covid Vaccines’ Possible IP Waiver In India</title>
		<link>http://www.tapanray.in/impact-of-covid-vaccines-possible-ip-waiver-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=impact-of-covid-vaccines-possible-ip-waiver-in-india</link>
		<comments>http://www.tapanray.in/impact-of-covid-vaccines-possible-ip-waiver-in-india/#comments</comments>
		<pubDate>Mon, 10 May 2021 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[Covid 2.0]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Covishield]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[SII]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[triumph]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[Vaccine Maitri]]></category>
		<category><![CDATA[Waiver]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10495</guid>
		<description><![CDATA[Just when Covid 2.0 rages in India with almost 4,000 people died in just 24 hours, scientists warn that Covid 3.0, and further waves are now ‘inevitable, reported Reuters on May 06, 2021. With hospitals running short of beds and oxygen during the &#8230; <a href="http://www.tapanray.in/impact-of-covid-vaccines-possible-ip-waiver-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/impact-of-covid-vaccines-possible-ip-waiver-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
